Aileron Therapeutics Inc (NASDAQ:ALRN) Expected to Announce Earnings of -$0.24 Per Share
Equities analysts expect Aileron Therapeutics Inc (NASDAQ:ALRN) to announce earnings per share (EPS) of ($0.24) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Aileron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.22). Aileron Therapeutics reported earnings of ($0.50) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 52%. The firm is scheduled to report its next earnings results on Wednesday, November 6th.
On average, analysts expect that Aileron Therapeutics will report full year earnings of ($1.14) per share for the current year, with EPS estimates ranging from ($1.27) to ($1.03). For the next financial year, analysts anticipate that the firm will post earnings of ($0.87) per share, with EPS estimates ranging from ($0.91) to ($0.81). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Aileron Therapeutics.
Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.03).
A number of institutional investors have recently made changes to their positions in the business. Jennison Associates LLC lifted its position in Aileron Therapeutics by 649.6% during the first quarter. Jennison Associates LLC now owns 2,040,255 shares of the company’s stock valued at $3,828,000 after purchasing an additional 1,768,073 shares during the last quarter. Deutsche Bank AG lifted its position in Aileron Therapeutics by 432.9% during the fourth quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock valued at $108,000 after purchasing an additional 104,932 shares during the last quarter. Finally, BlackRock Inc. lifted its position in Aileron Therapeutics by 179.6% during the second quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock valued at $36,000 after purchasing an additional 31,787 shares during the last quarter. Institutional investors and hedge funds own 29.17% of the company’s stock.
ALRN stock opened at $0.61 on Friday. The company has a 50 day moving average price of $0.60. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.04 and a quick ratio of 6.04. Aileron Therapeutics has a 12 month low of $0.44 and a 12 month high of $4.10.
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Read More: Should You Consider an Index Fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.